Characterization of RIT1 signaling by proteome, phosphoproteome, and transcriptome profiling



April Lo^{1,2}, Shriya Kamlapurkar¹, Kristin Holmes¹, Filip Mundt^{3,4}, Sitapriya Moorthi¹, Steven A. Carr³, Philipp Mertins, Alice Berger^{1,2}



¹ Human Biology Division, Fred Hutchinson Cancer Research Center ² Department of Genome Sciences, University of Washington ³Proteomics Platform, Broad Institute of MIT and Harvard ⁴Department of Oncology-Pathology, Karolinska Institute

BGN

SDC1

TPM4

TPM2

GPC1

TPM1

SFRP1

MCM7

SNTB1

GLIPR1

GAS1


DST

Background

Ras-like-in-all-tissues (*RIT1*) is a small GTPase of the Ras family that shares 50% homology with KRAS.

RIT1 is mutated in 2% of lung adenocarcinomas and amplified in a further 7-14%¹.


However, while RIT1's role in some Ras-related pathways has been investigated, there has been no unbiased mapping of downstream RIT1 regulation and signaling pathways in human cells.



Questions


- Does RIT1 regulate the same pathways and processes as KRAS?
- How does increased expression of wild-type RIT1 affect signaling, compared to RIT1 and KRAS oncogenic variants?


Methods




We transduced wild-type and oncogenic variant KRAS and RIT1 into AALE cells, a non-transformed, immortalized, human lung epithelial

We then performed proteomics and phosproteomics profiling by LC/MS-MS and transcriptomic profiling by RNA-seq.









Results

RIT1^{WT} and RIT1^{M901} induce changes in the proteome and phosproteome similar to KRAS variants




The proteome and phosphoproteome profiles of KRAS^{G12V} and KRAS^{Q61H} were highly correlated with each other, and with the proteome and phosphoproteomes of RIT1^{WT} and RIT1^{M90I} (r = 0.7-0.85).




Among the top proteins with increased abundance in KRAS variant and RIT1 cells was FOSL1, a transcription factor known to be upregulated by RAS.

Similarly, TXNIP, a protein shown to be suppressed by HRASG12V, was among the top proteins with decreased abundance.


RIT1^{WT} and RIT1^{M90I} also induce changes in the transcriptome similar to KRAS variants







Gene set enrichment analysis of upregulated transcripts show expected increase in activity of KRAS signaling pathways.


Proteome and transcriptome profiles are moderately correlated










RIT1 promotes an epithelial-to-mesenchymal transition







Quantification of Vimentin, Snail, and Slug mRNA by qRT-PCR indicate these EMT genes are indeed upregulated at the transcript level.



In line with a functional EMT, RIT1-transformed cells show enhanced migration in a scratch assay, with RIT1^{WT} and RIT1^{M901} closing the scratch wound up to 1.5x and 1.9x faster than vector control cells respectively.

Conclusions

- RIT1 and KRAS signaling networks exhibit overall similarity, suggesting that oncogenic RIT1 can hijact and activate canonical Ras effector pathways.
- Amplification of wild-type RIT1 expression phenocopies oncogenic RIT1 activation
- Both RIT1^{WT} overexpression and RIT1^{M901} promote an EMT phenotype

Acknowledgements

This work was supported in part by an NSF IGERT DGE-1258485 fellowship. RNA-sequencing was performed by the Fred Hutch Genomics Shared Resource. Microscopy and image analysis was performed with assistance from Fred Hutch Cellular Imaging Shared Resource.

References

1. TCGA, Nature, 2014. 2. Keenan et al., NAR, 2019.

Future Directions

- Investigate oncogenic properties of amplified wild-type RIT1 in human tumors
- Further determine how RIT1 regulates EMT and whether it does so *in vivo*
- Analyze RNA-seq and phosphoproteomic data further to determine how RIT1 and KRAS affects alternative splicing processes

Contact

Email: aprillo@uw.edu or alo2@fredhutch.org

Twitter: @pamyl
GitHub: aprilflow

Berger Lab (C2-201)